A look at CardioFlux MCG's most important clinical registries, trials & milestones.
Ascension St. John enrolls its first MICRO (T) patient.
The Christ Hospital enrolls its first MICRO (T) patient.
The MICRO(T) study is launched at The Christ Hospital under principal investigator Odayme Quesada.
Dr. Nathaniel Dittoe of Kettering Health leads the launch of the The MAGNETO-PET Registry as the first site open to enrollment.
The Enrollment Goal for the MICRO study is met for the primary objective analysis.
The first clinical study subject in the M-CAV trial is enrolled at The Cleveland Clinic.
Dr. Paul Cremer launches his pilot clinical trial program, M-CAV, at the Cleveland Clinic.
Cleveland Clinic enrolls its first patient.
The MICRO study is launched at The Cleveland Clinic, under Principal Investigator Dr. Khaled Ziada.
The Principal Investigators join Genetesis in Detroit, Michigan for early exploratory review of interim analysis data in the ACCMED trial.
The Enrollment Goal for the ACCMED clinical trial is met for primary endpoint analysis.
The MICRO study expands into a multicenter trial under the direction of Dr. Edouard Daher with Ascension St. John's Hospital in Detroit, Michigan.
The first clinical trial subject in the ACCMED study is enrolled at Ascension St. John by Dr. Claire Pearson.
The ACCMED study expands to include Wake Forest University in Winston-Salem, North Carolina under the direction of Dr. Simon Mahler and Dr. James Stopyra.
The ACCMED Study is expanded to include Ascension St. John's Hospital in Detroit, Michigan under the direction of Principal Investigator Dr. Claire Pearson.
The first clinical study subject in the MICRO trial is enrolled at The Christ Hospital by Dr. Odayme Quesada in Cincinnati, Ohio.
Dr. Odayme Quesada with The Christ Hospital's Heart & Vascular Center partners with Genetesis to launch the MICRO 1.0 Clinical Trial.
The ACCMED study expands to include Beaumont Royal Oak Hospital in Detroit, Michigan under the direction of Dr. Carol Clark.
The ACCED clinical trial is launched at the Cleveland Clinic under Lead Principal Investigator Dr. Sharon Mace.